X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Pharma Giants Withdraw From Russia Owing To Ukraine Invasion

Content Team by Content Team
21st March 2022
in News
Indian Pharmaceutical Industry In 2021 And The Road Ahead

Hundreds of businesses have announced a suspension or withdrawal of operations in Russia since itsĀ invasion of Ukraine. Some of the most recent companies to join the increasing list were Eli Lilly, Novartis, and AbbVie.

Eli Lilly has halted the sale of “non-essential pharmaceuticals” to Russia, focusing its businesses in the nation entirely on cancer and diabetes, according to a statement released Tuesday by the drugmaker from Indianapolis.

Lilly has announced that it will contribute any revenues from Russia to humanitarian charity groups, joining Pfizer in this endeavor. In Russia, it has also slashed all funding, promotional efforts, and fresh clinical trials. Since 1989, Lilly has been active in Russia. According to the company’s Russian website, in addition to cancer and diabetes medications, the company also sells medicines for osteoporosis and mental illnesses.

From a humane aspect, suspending all activities or withdrawing altogether from Russia is not an option for pharmaceutical companies, unlike other corporate sectors. Another major diabetic treatment supplier, Novo Nordisk, has stated that it will do everything possible to sustain supplies both in Ukraine and Russia.

The corporation is “deeply concerned” about Russia’s invasion of Ukraine and claims it stays in touch with its staff there on a daily basis. They have halted further marketing and scientific expenditures in Russia and are concentrating their efforts on assisting their local workers and ensuring that over 650,000 patients may continue to receive their life-saving medication, saysĀ a Novo Nordisk representative in an email. The Russian factory still happens to beĀ operational, supplying drugs to Russian patients, the email noted.

In Russia, where there are presently more than 3,000 patients engaged in research, the company has suspended the launch of new clinical studies and halted active registration of new patients, according to Novo. Novo has done the same in Ukraine as well, where 900 patients are currently engaged in clinical trials.

Pfizer and Bayer took critical decisions earlier this week: both companies are suspending operations in Russia and restricting their supply of vital medicines. Pfizer has stated that any earnings it receives from Russia will be used to help humanitarian initiatives in Ukraine. In a similar fashion, AbbVie revealed that it had temporarily halted operations in Russia for its aesthetics products. In Ukraine and Russia, it has also halted the start of new clinical trials as well as the screening and enrolment in existing studies.

Merck & Co., another American drug maker, has announced that it will no longer invest in Russia. For humanitarian reasons, they have a commitment to continue to distribute potentially vital and life-changing vaccinations to patients in Russia, saidĀ a Merck representative. Novartis and its generics company, Sandoz, have chosen to halt all investments and commercial marketing operations in Russia, according to a freshly updated blog post. Novartis stated that it is committed to ensuring access to medications for individuals in both nations.

Meanwhile, a spokeswoman said thatĀ Novartis’ cross-town rival, Roche, is still operating in Russia, with a focus on delivering essential medications and some diagnosticsĀ in conformity with international humanitarian law.

Previous Post

AstraZeneca Makes Advances In Fight Against Ovarian Cancer

Next Post

Germany Signs Vaccine Deals To Prepare For Future Outbreaks

Related Posts

DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Clinical Trials

Bio-Rad to Acquire Stilla Technologies by Q3 2025

28th February 2025
Next Post
Intravacc partners with Wageningen Bioveterinary Research and Utrecht University to develop an intranasal COVID-19 vaccine

Germany Signs Vaccine Deals To Prepare For Future Outbreaks

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

Ā© 2017 Copyright Ā© Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

Ā© 2017 Copyright Ā© Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In